Assessment of target-mediated uptake with immuno-PET: analysis of a phase I clinical trial with an anti-CD44 antibody View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2018-01-22

AUTHORS

Yvonne W. S. Jauw, Marc C. Huisman, Tapan K. Nayak, Danielle J. Vugts, Randolph Christen, Valerie Meresse Naegelen, Dominik Ruettinger, Florian Heil, Adriaan A. Lammertsma, Henk M. W. Verheul, Otto S. Hoekstra, Guus A. M. S. van Dongen, C. Willemien Menke-van der Houven van Oordt

ABSTRACT

BackgroundIdeally, monoclonal antibodies provide selective treatment by targeting the tumour, without affecting normal tissues. Therefore, antibody imaging is of interest, preferably in early stages of drug development. However, the imaging signal consists of specific, as well as non-specific, uptake. The aim of this study was to assess specific, target-mediated uptake in normal tissues, with immuno-PET in a phase I dose escalation study, using the anti-CD44 antibody RG7356 as example.ResultsData from thirteen patients with CD44-expressing solid tumours included in an imaging sub-study of a phase I dose escalation clinical trial using the anti-CD44 antibody RG7356 was analysed. 89Zirconium-labelled RG7356 (1 mg; 37 MBq) was administered after a variable dose of unlabelled RG7356 (0 to 675 mg). Tracer uptake in normal tissues (liver, spleen, kidney, lung, bone marrow, brain and blood pool) was used to calculate the area under the time antibody concentration curve (AUC) and expressed as tissue-to-blood AUC ratios.Within the dose range of 1 to 450 mg, tissue-to-blood AUC ratios decreased from 10.6 to 0.75 ± 0.16 for the spleen, 7.5 to 0.86 ± 0.18 for the liver, 3.6 to 0.48 ± 0.13 for the bone marrow, 0.69 to 0.26 ± 0.1 for the lung and 1.29 to 0.56 ± 0.14 for the kidney, indicating dose-dependent uptake. In all patients receiving ≥ 450 mg (n = 7), tumour uptake of the antibody was observed.ConclusionsThis study demonstrates how immuno-PET in a dose escalation study provides a non-invasive technique to quantify dose-dependent uptake in normal tissues, indicating specific, target-mediated uptake. More... »

PAGES

6

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s13550-018-0358-8

DOI

http://dx.doi.org/10.1186/s13550-018-0358-8

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1100562510

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/29356983


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Hematology, VU University Medical Center, Amsterdam, the Netherlands", 
          "id": "http://www.grid.ac/institutes/grid.16872.3a", 
          "name": [
            "Department of Hematology, VU University Medical Center, Amsterdam, the Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Jauw", 
        "givenName": "Yvonne W. S.", 
        "id": "sg:person.0716757006.38", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0716757006.38"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam, the Netherlands", 
          "id": "http://www.grid.ac/institutes/grid.16872.3a", 
          "name": [
            "Department of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam, the Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Huisman", 
        "givenName": "Marc C.", 
        "id": "sg:person.01006327107.21", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01006327107.21"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Pharma Research and Early Development, Roche Innovation Center, Basel, Switzerland", 
          "id": "http://www.grid.ac/institutes/grid.417570.0", 
          "name": [
            "Department of Pharma Research and Early Development, Roche Innovation Center, Basel, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nayak", 
        "givenName": "Tapan K.", 
        "id": "sg:person.01151243310.49", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01151243310.49"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam, the Netherlands", 
          "id": "http://www.grid.ac/institutes/grid.16872.3a", 
          "name": [
            "Department of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam, the Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Vugts", 
        "givenName": "Danielle J.", 
        "id": "sg:person.0665425270.49", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0665425270.49"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Product Development, Safety Risk Management, Roche, Basel, Switzerland", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Department of Product Development, Safety Risk Management, Roche, Basel, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Christen", 
        "givenName": "Randolph", 
        "id": "sg:person.01264517270.59", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01264517270.59"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Pharma Research and Early Development, Roche Innovation Center, Basel, Switzerland", 
          "id": "http://www.grid.ac/institutes/grid.417570.0", 
          "name": [
            "Department of Pharma Research and Early Development, Roche Innovation Center, Basel, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Naegelen", 
        "givenName": "Valerie Meresse", 
        "id": "sg:person.01332724057.54", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01332724057.54"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Pharma Research and Early Development, Roche Innovation Center, Munich, Germany", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Department of Pharma Research and Early Development, Roche Innovation Center, Munich, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ruettinger", 
        "givenName": "Dominik", 
        "id": "sg:person.010731737223.38", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010731737223.38"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Pharma Research and Early Development, Roche Innovation Center, Munich, Germany", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Department of Pharma Research and Early Development, Roche Innovation Center, Munich, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Heil", 
        "givenName": "Florian", 
        "id": "sg:person.01216023341.55", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01216023341.55"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam, the Netherlands", 
          "id": "http://www.grid.ac/institutes/grid.16872.3a", 
          "name": [
            "Department of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam, the Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lammertsma", 
        "givenName": "Adriaan A.", 
        "id": "sg:person.01352511753.53", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01352511753.53"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medical Oncology, VU University Medical Center, Amsterdam, the Netherlands", 
          "id": "http://www.grid.ac/institutes/grid.16872.3a", 
          "name": [
            "Department of Medical Oncology, VU University Medical Center, Amsterdam, the Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Verheul", 
        "givenName": "Henk M. W.", 
        "id": "sg:person.011543041217.55", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011543041217.55"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam, the Netherlands", 
          "id": "http://www.grid.ac/institutes/grid.16872.3a", 
          "name": [
            "Department of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam, the Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hoekstra", 
        "givenName": "Otto S.", 
        "id": "sg:person.0621551653.25", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0621551653.25"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam, the Netherlands", 
          "id": "http://www.grid.ac/institutes/grid.16872.3a", 
          "name": [
            "Department of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam, the Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "van Dongen", 
        "givenName": "Guus A. M. S.", 
        "id": "sg:person.0732223564.35", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0732223564.35"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medical Oncology, VU University Medical Center, Amsterdam, the Netherlands", 
          "id": "http://www.grid.ac/institutes/grid.16872.3a", 
          "name": [
            "Department of Medical Oncology, VU University Medical Center, Amsterdam, the Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Menke-van der Houven van Oordt", 
        "givenName": "C. Willemien", 
        "id": "sg:person.0704276650.01", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0704276650.01"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/nrm1004", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044326367", 
          "https://doi.org/10.1038/nrm1004"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00204-014-1424-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033128567", 
          "https://doi.org/10.1007/s00204-014-1424-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10928-016-9482-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033784724", 
          "https://doi.org/10.1007/s10928-016-9482-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nbt1210-1248", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002756332", 
          "https://doi.org/10.1038/nbt1210-1248"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00259-009-1263-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005085942", 
          "https://doi.org/10.1007/s00259-009-1263-1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/clpt.2010.12", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037850597", 
          "https://doi.org/10.1038/clpt.2010.12"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nprot.2010.13", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015342974", 
          "https://doi.org/10.1038/nprot.2010.13"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2018-01-22", 
    "datePublishedReg": "2018-01-22", 
    "description": "BackgroundIdeally, monoclonal antibodies provide selective treatment by targeting the tumour, without affecting normal tissues. Therefore, antibody imaging is of interest, preferably in early stages of drug development. However, the imaging signal consists of specific, as well as non-specific, uptake. The aim of this study was to assess specific, target-mediated uptake in normal tissues, with immuno-PET in a phase I dose escalation study, using the anti-CD44 antibody RG7356 as example.ResultsData from thirteen patients with CD44-expressing solid tumours included in an imaging sub-study of a phase I dose escalation clinical trial using the anti-CD44 antibody RG7356 was analysed. 89Zirconium-labelled RG7356 (1 mg; 37 MBq) was administered after a variable dose of unlabelled RG7356 (0 to 675 mg). Tracer uptake in normal tissues (liver, spleen, kidney, lung, bone marrow, brain and blood pool) was used to calculate the area under the time antibody concentration curve (AUC) and expressed as tissue-to-blood AUC ratios.Within the dose range of 1 to 450 mg, tissue-to-blood AUC ratios decreased from 10.6 to 0.75 \u00b1 0.16 for the spleen, 7.5 to 0.86 \u00b1 0.18 for the liver, 3.6 to 0.48 \u00b1 0.13 for the bone marrow, 0.69 to 0.26 \u00b1 0.1 for the lung and 1.29 to 0.56 \u00b1 0.14 for the kidney, indicating dose-dependent uptake. In all patients receiving \u2265 450 mg (n = 7), tumour uptake of the antibody was observed.ConclusionsThis study demonstrates how immuno-PET in a dose escalation study provides a non-invasive technique to quantify dose-dependent uptake in normal tissues, indicating specific, target-mediated uptake.", 
    "genre": "article", 
    "id": "sg:pub.10.1186/s13550-018-0358-8", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.8570267", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1045165", 
        "issn": [
          "2191-219X"
        ], 
        "name": "EJNMMI Research", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "8"
      }
    ], 
    "keywords": [
      "blood AUC ratio", 
      "immuno-PET", 
      "dose-dependent uptake", 
      "normal tissues", 
      "escalation study", 
      "clinical trials", 
      "AUC ratio", 
      "phase I", 
      "phase I clinical trial", 
      "dose-escalation study", 
      "escalation clinical trial", 
      "antibody imaging", 
      "RG7356", 
      "bone marrow", 
      "tumor uptake", 
      "solid tumors", 
      "non-invasive technique", 
      "CD44 antibody", 
      "variable dose", 
      "monoclonal antibodies", 
      "ConclusionsThis study", 
      "dose range", 
      "antibodies", 
      "patients", 
      "drug development", 
      "tumors", 
      "tissue", 
      "selective treatment", 
      "concentration curve", 
      "trials", 
      "uptake", 
      "early stages", 
      "ResultsData", 
      "lung", 
      "spleen", 
      "kidney", 
      "marrow", 
      "study", 
      "liver", 
      "dose", 
      "CD44", 
      "treatment", 
      "imaging", 
      "aim", 
      "assessment", 
      "ratio", 
      "stage", 
      "tracer", 
      "development", 
      "curves", 
      "analysis", 
      "area", 
      "technique", 
      "interest", 
      "range", 
      "signals", 
      "example"
    ], 
    "name": "Assessment of target-mediated uptake with immuno-PET: analysis of a phase I clinical trial with an anti-CD44 antibody", 
    "pagination": "6", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1100562510"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s13550-018-0358-8"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "29356983"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s13550-018-0358-8", 
      "https://app.dimensions.ai/details/publication/pub.1100562510"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-05-20T07:34", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220519/entities/gbq_results/article/article_768.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1186/s13550-018-0358-8"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s13550-018-0358-8'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s13550-018-0358-8'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s13550-018-0358-8'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s13550-018-0358-8'


 

This table displays all metadata directly associated to this object as RDF triples.

244 TRIPLES      22 PREDICATES      90 URIs      75 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s13550-018-0358-8 schema:about anzsrc-for:11
2 anzsrc-for:1103
3 schema:author N57d39d7085f14033825955435683eb1d
4 schema:citation sg:pub.10.1007/s00204-014-1424-2
5 sg:pub.10.1007/s00259-009-1263-1
6 sg:pub.10.1007/s10928-016-9482-0
7 sg:pub.10.1038/clpt.2010.12
8 sg:pub.10.1038/nbt1210-1248
9 sg:pub.10.1038/nprot.2010.13
10 sg:pub.10.1038/nrm1004
11 schema:datePublished 2018-01-22
12 schema:datePublishedReg 2018-01-22
13 schema:description BackgroundIdeally, monoclonal antibodies provide selective treatment by targeting the tumour, without affecting normal tissues. Therefore, antibody imaging is of interest, preferably in early stages of drug development. However, the imaging signal consists of specific, as well as non-specific, uptake. The aim of this study was to assess specific, target-mediated uptake in normal tissues, with immuno-PET in a phase I dose escalation study, using the anti-CD44 antibody RG7356 as example.ResultsData from thirteen patients with CD44-expressing solid tumours included in an imaging sub-study of a phase I dose escalation clinical trial using the anti-CD44 antibody RG7356 was analysed. 89Zirconium-labelled RG7356 (1 mg; 37 MBq) was administered after a variable dose of unlabelled RG7356 (0 to 675 mg). Tracer uptake in normal tissues (liver, spleen, kidney, lung, bone marrow, brain and blood pool) was used to calculate the area under the time antibody concentration curve (AUC) and expressed as tissue-to-blood AUC ratios.Within the dose range of 1 to 450 mg, tissue-to-blood AUC ratios decreased from 10.6 to 0.75 ± 0.16 for the spleen, 7.5 to 0.86 ± 0.18 for the liver, 3.6 to 0.48 ± 0.13 for the bone marrow, 0.69 to 0.26 ± 0.1 for the lung and 1.29 to 0.56 ± 0.14 for the kidney, indicating dose-dependent uptake. In all patients receiving ≥ 450 mg (n = 7), tumour uptake of the antibody was observed.ConclusionsThis study demonstrates how immuno-PET in a dose escalation study provides a non-invasive technique to quantify dose-dependent uptake in normal tissues, indicating specific, target-mediated uptake.
14 schema:genre article
15 schema:inLanguage en
16 schema:isAccessibleForFree true
17 schema:isPartOf Nc158930550264858bdf4b328e03ba4b6
18 Nc6395caa79ac45e094e17989635fa4e5
19 sg:journal.1045165
20 schema:keywords AUC ratio
21 CD44
22 CD44 antibody
23 ConclusionsThis study
24 RG7356
25 ResultsData
26 aim
27 analysis
28 antibodies
29 antibody imaging
30 area
31 assessment
32 blood AUC ratio
33 bone marrow
34 clinical trials
35 concentration curve
36 curves
37 development
38 dose
39 dose range
40 dose-dependent uptake
41 dose-escalation study
42 drug development
43 early stages
44 escalation clinical trial
45 escalation study
46 example
47 imaging
48 immuno-PET
49 interest
50 kidney
51 liver
52 lung
53 marrow
54 monoclonal antibodies
55 non-invasive technique
56 normal tissues
57 patients
58 phase I
59 phase I clinical trial
60 range
61 ratio
62 selective treatment
63 signals
64 solid tumors
65 spleen
66 stage
67 study
68 technique
69 tissue
70 tracer
71 treatment
72 trials
73 tumor uptake
74 tumors
75 uptake
76 variable dose
77 schema:name Assessment of target-mediated uptake with immuno-PET: analysis of a phase I clinical trial with an anti-CD44 antibody
78 schema:pagination 6
79 schema:productId N6edbdef3e21f4607a18a712ce75b3071
80 N7d1d0cca54894b3fa841625ee1dcbdd9
81 Ne16554f5304c41eeaaa554c960d07b14
82 schema:sameAs https://app.dimensions.ai/details/publication/pub.1100562510
83 https://doi.org/10.1186/s13550-018-0358-8
84 schema:sdDatePublished 2022-05-20T07:34
85 schema:sdLicense https://scigraph.springernature.com/explorer/license/
86 schema:sdPublisher N59c9140cc11d4f9380a375c007e0040b
87 schema:url https://doi.org/10.1186/s13550-018-0358-8
88 sgo:license sg:explorer/license/
89 sgo:sdDataset articles
90 rdf:type schema:ScholarlyArticle
91 N04e43f0ded8a4e1aa887534f27bdc57c rdf:first sg:person.01332724057.54
92 rdf:rest Ne6470874f75046bea222897010d59adf
93 N0b7d715f09554da3aabb6b572b3ada7c rdf:first sg:person.01151243310.49
94 rdf:rest N364e7806ecde4940a2765c51143fc146
95 N17b0597ce8bd46f8814c714a1addf10b rdf:first sg:person.01352511753.53
96 rdf:rest N3569b3ffd2484f09ab2740283868a213
97 N25033dead860403eb720e41164ba1f29 rdf:first sg:person.0621551653.25
98 rdf:rest N35e8fbfb74e34adfa038fb93acdeda4f
99 N3569b3ffd2484f09ab2740283868a213 rdf:first sg:person.011543041217.55
100 rdf:rest N25033dead860403eb720e41164ba1f29
101 N35e8fbfb74e34adfa038fb93acdeda4f rdf:first sg:person.0732223564.35
102 rdf:rest N743bb10a89934ea488b074ed8ae78203
103 N364e7806ecde4940a2765c51143fc146 rdf:first sg:person.0665425270.49
104 rdf:rest N5848e9b8ed94484b86f1a6bd2c01ef58
105 N57d39d7085f14033825955435683eb1d rdf:first sg:person.0716757006.38
106 rdf:rest Nd694f2ccccc344f1aded692eca74c85c
107 N5848e9b8ed94484b86f1a6bd2c01ef58 rdf:first sg:person.01264517270.59
108 rdf:rest N04e43f0ded8a4e1aa887534f27bdc57c
109 N59c9140cc11d4f9380a375c007e0040b schema:name Springer Nature - SN SciGraph project
110 rdf:type schema:Organization
111 N6edbdef3e21f4607a18a712ce75b3071 schema:name pubmed_id
112 schema:value 29356983
113 rdf:type schema:PropertyValue
114 N743bb10a89934ea488b074ed8ae78203 rdf:first sg:person.0704276650.01
115 rdf:rest rdf:nil
116 N7d1d0cca54894b3fa841625ee1dcbdd9 schema:name doi
117 schema:value 10.1186/s13550-018-0358-8
118 rdf:type schema:PropertyValue
119 Nc158930550264858bdf4b328e03ba4b6 schema:issueNumber 1
120 rdf:type schema:PublicationIssue
121 Nc6395caa79ac45e094e17989635fa4e5 schema:volumeNumber 8
122 rdf:type schema:PublicationVolume
123 Nd694f2ccccc344f1aded692eca74c85c rdf:first sg:person.01006327107.21
124 rdf:rest N0b7d715f09554da3aabb6b572b3ada7c
125 Ne16554f5304c41eeaaa554c960d07b14 schema:name dimensions_id
126 schema:value pub.1100562510
127 rdf:type schema:PropertyValue
128 Ne6470874f75046bea222897010d59adf rdf:first sg:person.010731737223.38
129 rdf:rest Nf7e88cf465d54d51bbdeb2ff8e958c8b
130 Nf7e88cf465d54d51bbdeb2ff8e958c8b rdf:first sg:person.01216023341.55
131 rdf:rest N17b0597ce8bd46f8814c714a1addf10b
132 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
133 schema:name Medical and Health Sciences
134 rdf:type schema:DefinedTerm
135 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
136 schema:name Clinical Sciences
137 rdf:type schema:DefinedTerm
138 sg:grant.8570267 http://pending.schema.org/fundedItem sg:pub.10.1186/s13550-018-0358-8
139 rdf:type schema:MonetaryGrant
140 sg:journal.1045165 schema:issn 2191-219X
141 schema:name EJNMMI Research
142 schema:publisher Springer Nature
143 rdf:type schema:Periodical
144 sg:person.01006327107.21 schema:affiliation grid-institutes:grid.16872.3a
145 schema:familyName Huisman
146 schema:givenName Marc C.
147 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01006327107.21
148 rdf:type schema:Person
149 sg:person.010731737223.38 schema:affiliation grid-institutes:None
150 schema:familyName Ruettinger
151 schema:givenName Dominik
152 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010731737223.38
153 rdf:type schema:Person
154 sg:person.01151243310.49 schema:affiliation grid-institutes:grid.417570.0
155 schema:familyName Nayak
156 schema:givenName Tapan K.
157 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01151243310.49
158 rdf:type schema:Person
159 sg:person.011543041217.55 schema:affiliation grid-institutes:grid.16872.3a
160 schema:familyName Verheul
161 schema:givenName Henk M. W.
162 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011543041217.55
163 rdf:type schema:Person
164 sg:person.01216023341.55 schema:affiliation grid-institutes:None
165 schema:familyName Heil
166 schema:givenName Florian
167 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01216023341.55
168 rdf:type schema:Person
169 sg:person.01264517270.59 schema:affiliation grid-institutes:None
170 schema:familyName Christen
171 schema:givenName Randolph
172 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01264517270.59
173 rdf:type schema:Person
174 sg:person.01332724057.54 schema:affiliation grid-institutes:grid.417570.0
175 schema:familyName Naegelen
176 schema:givenName Valerie Meresse
177 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01332724057.54
178 rdf:type schema:Person
179 sg:person.01352511753.53 schema:affiliation grid-institutes:grid.16872.3a
180 schema:familyName Lammertsma
181 schema:givenName Adriaan A.
182 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01352511753.53
183 rdf:type schema:Person
184 sg:person.0621551653.25 schema:affiliation grid-institutes:grid.16872.3a
185 schema:familyName Hoekstra
186 schema:givenName Otto S.
187 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0621551653.25
188 rdf:type schema:Person
189 sg:person.0665425270.49 schema:affiliation grid-institutes:grid.16872.3a
190 schema:familyName Vugts
191 schema:givenName Danielle J.
192 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0665425270.49
193 rdf:type schema:Person
194 sg:person.0704276650.01 schema:affiliation grid-institutes:grid.16872.3a
195 schema:familyName Menke-van der Houven van Oordt
196 schema:givenName C. Willemien
197 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0704276650.01
198 rdf:type schema:Person
199 sg:person.0716757006.38 schema:affiliation grid-institutes:grid.16872.3a
200 schema:familyName Jauw
201 schema:givenName Yvonne W. S.
202 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0716757006.38
203 rdf:type schema:Person
204 sg:person.0732223564.35 schema:affiliation grid-institutes:grid.16872.3a
205 schema:familyName van Dongen
206 schema:givenName Guus A. M. S.
207 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0732223564.35
208 rdf:type schema:Person
209 sg:pub.10.1007/s00204-014-1424-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033128567
210 https://doi.org/10.1007/s00204-014-1424-2
211 rdf:type schema:CreativeWork
212 sg:pub.10.1007/s00259-009-1263-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005085942
213 https://doi.org/10.1007/s00259-009-1263-1
214 rdf:type schema:CreativeWork
215 sg:pub.10.1007/s10928-016-9482-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033784724
216 https://doi.org/10.1007/s10928-016-9482-0
217 rdf:type schema:CreativeWork
218 sg:pub.10.1038/clpt.2010.12 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037850597
219 https://doi.org/10.1038/clpt.2010.12
220 rdf:type schema:CreativeWork
221 sg:pub.10.1038/nbt1210-1248 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002756332
222 https://doi.org/10.1038/nbt1210-1248
223 rdf:type schema:CreativeWork
224 sg:pub.10.1038/nprot.2010.13 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015342974
225 https://doi.org/10.1038/nprot.2010.13
226 rdf:type schema:CreativeWork
227 sg:pub.10.1038/nrm1004 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044326367
228 https://doi.org/10.1038/nrm1004
229 rdf:type schema:CreativeWork
230 grid-institutes:None schema:alternateName Department of Pharma Research and Early Development, Roche Innovation Center, Munich, Germany
231 Department of Product Development, Safety Risk Management, Roche, Basel, Switzerland
232 schema:name Department of Pharma Research and Early Development, Roche Innovation Center, Munich, Germany
233 Department of Product Development, Safety Risk Management, Roche, Basel, Switzerland
234 rdf:type schema:Organization
235 grid-institutes:grid.16872.3a schema:alternateName Department of Hematology, VU University Medical Center, Amsterdam, the Netherlands
236 Department of Medical Oncology, VU University Medical Center, Amsterdam, the Netherlands
237 Department of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam, the Netherlands
238 schema:name Department of Hematology, VU University Medical Center, Amsterdam, the Netherlands
239 Department of Medical Oncology, VU University Medical Center, Amsterdam, the Netherlands
240 Department of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam, the Netherlands
241 rdf:type schema:Organization
242 grid-institutes:grid.417570.0 schema:alternateName Department of Pharma Research and Early Development, Roche Innovation Center, Basel, Switzerland
243 schema:name Department of Pharma Research and Early Development, Roche Innovation Center, Basel, Switzerland
244 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...